



# Buried Treasure: Bringing the Hidden Value of TMF Metrics to Light

Joanne Malia Regeneron Pharmaceuticals Janice Cassamajor Cencora Pharmalex





### **Meet the Speakers**

Joanne Malia

Title: Senior Director, Development Records Management

Organization: Regeneron Pharmaceuticals

Joanne Malia has served on the Steering Committee for the past 3 years and was the colead of the Change Control Board prior to that. She really enjoys the TMF and records in general and making the whole process easier and better quality while using metrics and working collaboratively with CROs and vendors. She is currently leading the TMF RM Risk Initiative and has been involved with inspections from FDA, MHRA, EMA, PMDA and others.

### Janice Cassamajor

Title: Director Customer Success


Organization: Cencora Pharmalex

Janice Cassamajor, brings 15 years of experience in the TMF (Trial Master File) realm. As a customer success leader, her focus lies in fostering enduring partnerships. She is deeply devoted to upholding TMF integrity and is driven by a desire to assist others in attaining excellence in TMF management.

### **Disclaimer and Disclosures**

- The views and opinions expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of CDISC.
- The authors have no real or apparent conflicts of interest to report.





## Agenda

- 1. Value of the partnership
- 2. Use of data visualizations
- 3. Benefit to Quality


### **Collaborative Relationship**

- Improved TMF quality, completeness and timeliness to help ensure ongoing inspection-readiness
- Developed and implemented process innovation that increases efficiency and frees busy study teams from rote work
- Created a "virtuous circle" of continuous improvements in TMF management ad overall quality

#### How did we achieve this?

- Complete openness and transparency
- Collaboration with deep understanding
- Clear roles and responsibilities





- eTMF reports
- Team trackers
- Historical data

- Deep dives
- Individual testimonials



### **Example - Quality Issues by CRO**

5-10% 11-20% >20% Off Track

		Example Quality Is sues by CRO Representing % of Total Docs Approved per CRO																																		
CRO	Jan Qls	% of Total Docs su bmitted	Total docs su bmitted	Feb Qls	% of Total Docs su bmitted	Total docs su bmitted	Mar Qls	% of Total Docs s bmitted	Total docs su bmitted			_		_				_		_	_			Total docs su bmitted			Total docs su bmitted	Oct Qls	% of Total Docs si bmitted	Total docs su bmitted	<b>Nov</b> Qls	% of Total Docs su bmitted	Total docs su bmitted	<b>Dec</b> Qls	% of Total Docs su bmitted	Total docs su bmitted
A	437	6.30%	6987	555	6.10%	9144	774	6.60%	11672	764	6.60%	11504	750	5.60%	13511	616	4.80%	12717	519	4.50%	11532	471	4.60%	10343	598	5.60%	10603	832	6.20%	13477	927	6.6%	13993	865	6.1%	14191
В	66	18.10%	364	138	23.10%	598	203	21.60%	943	184	24.10%	762	196	21.90%	894	251	22.80%	1101	145	17.50%	827	284	20.30%	1402	198	11.40%	1742	202	25.20%	801	174	19.0%	915	160	17.1%	938
С	646	18.40%	1575	793	17.20%	4606	865	20.10%	4314	753	18.70%	4092	740	18.20%	4061	656	14.50%	4531	553	14.00%	3961	512	12.40%	4137	708	15.80%	4493	600	17.40%	3452	632	19.0%	3321	679	24.4%	2778
D	318	20.20%	1575	461	20.10%	2290	480	22.80%	2103	236	20.60%	1146	480	28.90%	1659	298	18.40%	1619	327	15.30%	2141	232	14.30%	1620	251	19.20%	1304	341	22.50%	1515	333	31.7%	1049	279	28.5%	979
E	466	23.90%	1946	686	24.70%	2778	673	27.40%	2328	540	24.10%	2241	632	22.30%	2839	617	17.80%	3459	410	12.10%	3378	548	20.20%	2717	516	18.30%	2812	558	20.10%	2783	645	25.0%	2576	571	23.5%	2434
F	504	25.00%	2020	572	29.90%	1913	646	34.90%	1820	513	31.10%	1648	765	27.20%	2816	488	23.50%	2077	481	22.00%	2191	495	25.60%	1936	398	20.30%	1958	362	19.70%	1839	446	23.5%	1899	342	23.4%	1461

Source: Regeneron; Cencora PharmaLex




### **Example -Top 5 Artifacts with highest Pre-Approval Qls**

#### **All Studies**

•	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
			Classification Qls	-	Classification Qls			Classification Qls		Classification Qls	Classification Qls	Classification Qls
•	IRB or IEC Decision 240	IRB or IEC Decision/ 311	IRB or IEC Decision 270	ICH-GCP Training Certificate 187	Informed Consent Form (ICF) 240	IRB or IEC Decision 173	Informed Consent Form (ICF) 170	Meeting Material (Trial) 224	IRB or IEC Decision 154	ICH-GCP Training Certificate 164	Site Evidence of Training 230	Meeting Material (Trial) 215
	Informed Consent Form (ICF) 151	ICH-GCP Training Certificate 286	ICH-GCP Training Certificate 259	Site Evidence of Training 176	IRB or IEC Decision 238	IP Shipment Documentation (IRT Only) 165	Meeting Material (Trial) 142	Informed Consent Form (ICF) 165	Meeting Material (Trial) 148	Meeting Material (Trial) 162	ICH-GCP Training Certificate 217	ICH-GCP Training Certificate 157
	ICH-GCP Training Certificate 147	IRB or IEC Submission 283	Informed Consent Form (ICF) 228	Informed Consent Form (ICF) 163	ICH-GCP Training Certificate 181	Relevant Communication s (Site) 148	Site Evidence of Training 124	ICH-GCP Training Certificate 132	ICH-GCP Training Certificate 147	Site Evidence of Training 147	Informed Consent Form (ICF) 182	IRB or IEC Decision 143
	IRB or IEC Submission 137	Informed Consent Form (ICF) 253	Site Evidence of Training 187	IP Shipment Documentatio n (IRT Only) 141	Relevant Communication s (Site) 178	Financial Disclosure Form (FDF) 155	IRB or IEC Decision 118	IRB or IEC Decision 118	Informed Consent Form (ICF) 124	IRB or IEC Decision 136	Meeting Material (Trial) 180	IRB or IEC Submission 135
	Site Evidence of Training 127	Site Evidence of Training 197	IRB or IEC Submission 159	Relevant Communicatio ns (Site) 139	IRB or IEC Submission 152	Meeting Material (Trial) 139	ICH-GCP Training Certificate 117	IRB or IEC Submission 107	IRB or IEC Submission 118	Informed Consent Form (ICF) 100	IRB or IEC Decision 162	Relevant Communication s (Site) 129



### **Example - QC findings by subcategory (top 5 by classification)**



Thank You!

